TG Therapeutics Says It Is On Path For Continued Growth Into End Of The Year And Into 2025 And Further Toward Long-term
TG Therapeutics Says It Is On Path For Continued Growth Into End Of The Year And Into 2025 And Further Toward Long-term
tg therapeutics表示它正在走向在今年年底和2025年以及更長期的持續增長道路。
Cash, cash equivalents and investment securities were $341.0 million as of September 30, 2024. The company said it anticipates that cash, cash equivalents and investment securities as of September 30, 2024, combined with the projected revenues from BRIUMVI, will be sufficient to fund business based on current operating plan.
截至2024年9月30日，現金、現金等價物和投資證券爲34100萬美元。公司表示，預計到2024年9月30日，結合來自BRIUMVI的預期收入，現金、現金等價物和投資證券將足以支持基於當前運營計劃的業務。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間